Recent press releases and announcements

News

An Open Letter to the Duchenne Community

Dear Members of the Duchenne Community: I want to thank you all for your support and encouragement over the last several years as Marathon worked to bring EMFLAZA™ (deflazacort) through the rigorous FDA approval process so patients in the United States would finally have access to this medicine and an understanding of this product. We […]

More

EMFLAZA™ (deflazacort) has just been FDA-approved

FOR IMMEDIATE RELEASE FDA Approves EMFLAZA™ (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older  New Drug is First Widely-Applicable Treatment for the Rare Fatal Genetic Disorder 17 Preclinical and Clinical Studies Completed to Support Approval  NORTHBROOK, Ill. – Feb. 9, 2017 – Marathon Pharmaceuticals, LLC […]

More

Marathon Pharmaceuticals Appoints New Members to its Advisory Board

NORTHBROOK, Ill. – Dec. 20, 2016 – Marathon Pharmaceuticals LLC, a biopharmaceutical company focused solely on developing treatments for rare diseases, today announced the appointment of three new members to its Advisory Board. “As a growing company it’s important that our Advisory Board members reflect diverse perspectives, share our commitment to patients and have experience […]

More

Marathon Pharmaceuticals Names Wanda Moebius Vice President of Communications

NORTHBROOK, Ill. – Oct. 31, 2016 – Marathon Pharmaceuticals LLC, a biopharmaceutical company developing treatments for rare diseases, today announced that Wanda Moebius has joined the company as vice president of communications. In her new role Moebius will oversee all communications activities working to educate the public on the value of developing needed treatment options […]

More

Marathon Pharmaceuticals Names Rick Munschauer, MD, FAAN as Chief Medical Officer

NORTHBROOK, Ill. – Oct. 6 2016 – Marathon Pharmaceuticals LLC, a biopharmaceutical company developing treatments for rare diseases, today announced that Rick Munschauer, MD, FAAN, has joined the company as Vice President and Chief Medical Officer, effective immediately. In his new role Dr. Munschauer will oversee clinical development, medical and scientific affairs activities for Marathon. […]

More